EGFR and non-small cell lung carcinoma: For example, the BCL2 inhibitor drug navitoclax was used in clinical trials, and shows efficacy in combination with other targeted therapy drugs, such as EGFR inhibitors, in EGFR-mutation-positive NSCLC [42].